COST-EFFECTIVENESS OF ALENDRONATE THERAPY FOR OSTEOPENIC POSTMENOPAUSAL WOMEN IN JAPAN

被引：0
|
作者：
Moriwaki, K. [1 ]
Komaba, H. [2 ]
Noto, S. [1 ]
Yanagisawa, S. [3 ]
Inoue, H. [1 ]
Takeshi, T. [1 ]
Fukagawa, M. [2 ]
Takahashi, H. E. [1 ]
机构：
[1] Niigata Univ Hlth & Welf, Niigata, Japan
[2] Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan
[3] Himeji Dokkyo Univ, Fac Pharmaceut Sci, Himeji, Hyogo, Japan
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.260
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A46 / A47
页数：2
相关论文
共 50 条
  • [31] The cost-effectiveness of osteoporosis screening strategies for postmenopausal women
    Nayak, S.
    Greenspan, S. L.
    Liu, H.
    Michaud, K.
    Owens, D. K.
    Roberts, M. S.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 : 410 - 411
  • [32] Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan
    Mori, Takahiro
    Crandall, Carolyn J.
    Fuji, Tomoko
    Ganz, David A.
    [J]. ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)
  • [33] Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan
    Takahiro Mori
    Carolyn J. Crandall
    Tomoko Fujii
    David A. Ganz
    [J]. Archives of Osteoporosis, 2021, 16
  • [34] COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE FOLLOWED BY ALENDRONATE VS ALENDRONATE MONOTHERAPY FOR THE PREVENTION OF FRACTURES IN POSTMENOPAUSAL US WOMEN AT INCREASED RISK OF FRACTURE
    Hiligsmann, M.
    Williams, S.
    Fitzpatrick, L.
    Silverman, S.
    Weiss, R. J.
    Reginster, J. Y.
    [J]. VALUE IN HEALTH, 2019, 22 : S243 - S243
  • [35] Comparative Effectiveness and Cost-Effectiveness of Strategies to Screen for Osteoporosis in Postmenopausal Women
    Schousboe, John T.
    Gourlay, Margaret L.
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 155 (11) : 788 - U117
  • [36] The cost-effectiveness of alendronate in the management of osteoporosis
    Kanis, John A.
    Adams, Judith
    Borgstrom, Fred
    Cooper, Cyrus
    Jonsson, Bengt
    Preedy, Danielle
    Selby, Peter
    Compston, Juliet
    [J]. BONE, 2008, 42 (01) : 4 - 15
  • [37] Strategies for the prevention of osteoporosis in postmenopausal women with hormone therapy and serms: Cost-effectiveness issues
    Torgerson, D
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S99 - S99
  • [38] Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial
    O. Ström
    F. Borgström
    S. S. Sen
    S. Boonen
    P. Haentjens
    O. Johnell
    J. A. Kanis
    [J]. Osteoporosis International, 2007, 18 : 1047 - 1061
  • [39] Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries -: an economic evaluation based on the fracture intervention trial
    Strom, O.
    Borgstrom, F.
    Sen, S. S.
    Boonen, S.
    Haentjens, P.
    Johnell, O.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 (08) : 1047 - 1061
  • [40] COST-EFFECTIVENESS OF BINOSTO (BUFFERED SOLUBLE ALENDRONATE 70 MG) EFFERVESCENT TABLET FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN ITALY
    Hiligsmann, M.
    Maggi, S.
    Onder, G.
    Galluzzo, L.
    Reginster, J. -Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S58 - S58
12345